Navigation Links
WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development
Date:7/31/2008

hire, New Hampshire.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007
2. WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award
3. WuXi PharmaTech Announces Third Quarter 2007 Results
4. WestChina-Frontier PharmaTech Awarded Full AAALAC Accreditation
5. WuXi PharmaTech (NYSE: WX) Mourns the Tragic Loss of Its Independent Director Shawn Wang
6. WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee
7. Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
8. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
9. Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars
10. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
11. WuXi PharmaTech 2007 Annual Report Available Online
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Beckman Coulter to Host Annual Business Review 2Health News:Researchers identify barriers to HPV vaccination uptake in low-income populations 2Health News:Researchers identify barriers to HPV vaccination uptake in low-income populations 3Health News:Orlando Company Develops New Technology Designed To Help Combat Hospital-Acquired Infections 2Health News:Orlando Company Develops New Technology Designed To Help Combat Hospital-Acquired Infections 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:New National Study Spotlights Importance of Federal Medicare Funding to Propping-Up Seniors' Deteriorating State Medicaid Benefits and Services 2Health News:New National Study Spotlights Importance of Federal Medicare Funding to Propping-Up Seniors' Deteriorating State Medicaid Benefits and Services 3
Breaking Medicine Technology:Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 2Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 3Free Wheelchair Mission Breaks List of Top 60 OC Nonprofits in 2009 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6American Red Cross Wins Court Injunction Against Striking Teamsters 62584 1American Red Cross Wins Court Injunction Against Striking Teamsters 62584 2Senate Approval of Mikulski Amendment Further Opens Health Care Bill to Massive Federal Funding of Abortion 62581 1Senate Approval of Mikulski Amendment Further Opens Health Care Bill to Massive Federal Funding of Abortion 62581 2Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 1Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 2